An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
Launched by M.D. ANDERSON CANCER CENTER · Oct 10, 2020
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new type of imaging called hyperpolarized magnetic resonance imaging (hpMRI) to see if it can help doctors understand how well treatment is working for patients with thyroid cancer and other cancers of the head and neck. Unlike a regular MRI, hpMRI uses a special contrast agent that may provide more detailed information about the tumor. This information could help doctors plan the best treatment options for patients undergoing radiation therapy or other treatments before surgery.
To be eligible for the trial, participants should be diagnosed with thyroid cancer or other head and neck cancers and be willing to provide consent for the study. Some people may not qualify, such as those with severe claustrophobia, certain heart conditions, or specific allergies. If you choose to participate, you can expect to undergo the hpMRI procedure, which is designed to gather valuable information about your cancer treatment response. This innovative approach is still in the early stages, so your involvement could contribute to important research that helps improve cancer care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be willing and able to provide informed consent
- • Be informed of the investigational nature of this study
- • Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment
- Exclusion Criteria:
- • Have a history of severe claustrophobia
- • Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)
- • Have a history of cardiac arrhythmia
- • Have an allergy to Gadavist intravenous contrast
- • Estimated glomerular filtration rate (eGFR) \< 30
- • If female, be pregnant or breast feeding at time of consent
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Stephen Y Lai
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials